Ruxolitinib for myelofibrosis: Indication of considerable added benefit

19 agosto 2014

In comparison with ‘best supportive care’, there is an indication that the new drug is better at relieving symptoms, and a hint of longer survival. Myelofibrosis is a rare disease of the bone marrow, in which the bone marrow is replaced by connective tissue. As a consequence of this so-called fibrosis, the bone marrow is no longer able to produce enough blood cells. Sometimes the spleen or the liver takes over some of the blood production. Then these organs enlarge and can cause abdominal discomfort and pain.